🔗 Share this article

While America continues making historic revisions to its immunization guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations throughout the pandemic and has zeroed in on alleged fatalities after Covid vaccination in her short time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Public health authorities had intended to announce radical changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would place the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A Shift at the FDA

This interim role could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing some childhood shot schedules in the US in order to be more in line with Denmark, a society with universal health coverage and a population roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, approval processes or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a major agency. She has no expertise in industry regulation.”

Past commissioners of CBER would “grasp laws and regulations and the science of drug development”, noted Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who ran CBER have had.”

This division has an immense range of responsibilities at the agency, she emphasized.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and more, and each of these need to be supervised,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant administrative aspect to the job, which manages in excess of 5,000 staff members. “It is a massive management job, if you perform it correctly,” she concluded.

Agency Reaction and Controversial Policies

In response to questions about Høeg’s credentials and whether this selection represents increased cooperation among agency officials on immunizations, a spokesperson responded that the “questions rely on incorrect presumptions”.

“Her experience is consistent with the functions of her role,” the spokesperson stated, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious one-day medication authorization process that reportedly troubled her preceding directors. “By what process are these medications being selected for this voucher program? Who makes the choices?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of pharmaceuticals, with the exception of immunizations.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, track record, Howard said. She published a study using non-validated crowd-sourced reports to estimate the rate of heart inflammation after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new government included changing regulations for new vaccines and halting “unnecessary” immunizations, she said after the election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of preventing teenage boys from receiving Covid vaccines.

“She is an complete ideologue who commences with her preconceived notions and reverse-engineers to accommodate the data in a highly deceptive, untruthful manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|